By Fineline Cube Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary YaoPharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology’s most difficult-to-treat, heavily pretreated populations.
Regulatory Milestone
| Element | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Conditional approval |
| Product | Velinotamig (GR1803), BCMA×CD3 bispecific antibody |
| Indication | Adults with relapsed or refractory multiple myeloma (RRMM) after ≥3 prior lines, incl. a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody |
| Date | 27 Aug 2026 |
| Licensee / MAH | Yaopharma, subsidiary of Fosun Pharma |
Drug Profile & Mechanism of Action
- Molecule: Velinotamig (GR1803), a BCMA×CD3 bispecific antibody
- Dual Targeting: Simultaneously targets both BCMA and CD3 antigens
- Mechanism: Redirects cytotoxic T cells to BCMA-expressing myeloma tumor cells and activates T cells to exert cytotoxic effects against the tumor cells
- Class Positioning: T-cell-engaging bispecific, a modality demonstrating high response rates in triple-class-exposed myeloma patients with limited remaining options
Licensing Structure
| Element | Detail |
|---|---|
| Agreement Date | May 2026 |
| Licensor | Chongqing Genrix Bio |
| Licensee | Yaopharma (subsidiary of Fosun Pharma) |
| Licensed Rights | Exclusive clinical development and commercialization of Velinotamig injection in mainland China, Hong Kong, Macao, and Taiwan |
| Additional Rights | Exclusive process research and manufacturing |
| Regulatory Role | Yaopharma serves as Marketing Authorization Holder (MAH) in the licensed territories |
Under the May 2026 license agreement with Chongqing Genrix Bio, Yaopharma obtained exclusive rights spanning clinical development, commercialization, process research, and manufacturing of Velinotamig injection across mainland China, Hong Kong, Macao, and Taiwan — and now serves as the product’s MAH. The swift progression from licensing to conditional approval underscores Fosun Pharma’s execution capability in in-licensing late-stage assets and driving them rapidly through the Chinese regulatory system.
Market Impact & Outlook
- Triple-Class-Exposed Population: The indication targets patients who have exhausted proteasome inhibitors, immunomodulators, and anti-CD38 antibodies — a segment with poor prognosis where T-cell engagers are reshaping the treatment paradigm
- BCMA Crowded-But-Growing Market: Velinotamig joins an expanding roster of BCMA-directed therapies in China, competing on efficacy depth, safety manageability, and commercial execution
- Fosun Oncology Franchise: The approval strengthens Fosun Pharma’s (SHA: 600196, HKG: 2196) hematology-oncology portfolio and validates its in-licensing strategy as a route to pipeline depth
- MAH Control: Holding full MAH rights across Greater China gives Yaopharma maximum pricing, distribution, and lifecycle flexibility in the licensed territories
Forward‑Looking Statements – This brief contains forward-looking statements regarding regulatory conditions, commercialization, and market competition. Conditional approval may be subject to post-marketing confirmatory requirements. Actual results may differ materially. Not investment advice.-Fineline Info & Tech